Search | Clinical Trials Finder

Conditions: Acute Bacterial Skin and Skin Structure Infections
Interventions: NXL103, Linezolid; Drug
Lead sponsor: Novexel Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Chula Vista, California • Fountain Valley, California • La Mesa, California + 7 more

Conditions: Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions: Omadacycline, Linezolid; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more

Conditions: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: TR-701 FA, Linezolid; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 30
States / cities: Dothan, Alabama • Anaheim, California • Buena Park, California + 22 more

Conditions: Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions: Dalbavancin, Vancomycin / Linezolid; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 55
States / cities: Anaheim, California • Azusa, California • Bellflower, California + 50 more

Conditions: Complicated Skin and Skin Structure Infections
Interventions: JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 27
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 23 more

Conditions: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Delafloxacin, Linezolid, Vancomycin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 31
States / cities: Mobile, Alabama • Montgomery, Alabama • Buena Park, California + 27 more

Conditions: Community Acquired Pneumonia
Interventions: lefamulin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more

Conditions: Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection, Infection, Bloodstream, Infection, Bacterial, Streptococcal Toxic Shock Syndrome
Interventions: Linezolid, Clindamycin; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms, Febrile Neutropenia
Interventions: CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Midwestern University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infections, Pneumonia
Interventions: Ceftaroline fosamil, IV Ceftriaxone and Vancomycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Long Beach, California • Oakland, California • Orange County, California + 10 more

Conditions: Febrile Neutropenia
Interventions: linezolid, vancomycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 16
States / cities: Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more

Conditions: Skin Diseases, Infectious
Interventions: PTK 0796, linezolid, moxifloxacin; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Fountain Valley, California • La Mesa, California • Oceanside, California + 4 more

Conditions: Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions: linezolid (Zyvox), vancomycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 108
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 71 more

Conditions: Pneumonia, Ventilator-Associated
Interventions: Vancomycin, Linezolid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 36
States / cities: Phoenix, Arizona • Palm Springs, California • Rancho Mirage, California + 22 more

Conditions: Bacterial Infections
Interventions: Zyvox® / Linezolid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Hartford, Connecticut + 15 more

Conditions: Gram Positive Infection
Interventions: linezolid, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
Interventions: Cefiderocol, Meropenem, Linezolid; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 15
States / cities: New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more

Conditions: Bacterial Infections
Interventions: Tedizolid (BAY119-2631), Placebo Tedizolid (BAY119-2631), Linezolid, Placebo Linezolid; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 2 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Isolate, Linezolid
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infectious Skin Disease, Bacterial Skin Disease
Interventions: PTK 0796, Linezolid; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 11
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 8 more

Conditions: Skin Diseases, Bacterial
Interventions: Intravenous iclaprim, Intravenous linezolid; Drug
Lead sponsor: Arpida AG; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Naperville, Illinois • Casper, Wyoming

Conditions: Diabetic Foot Infection
Interventions: contezolid acefosamil (IV)/contezolid (PO), Linezolid (IV and PO); Drug
Lead sponsor: MicuRx; Industry
Eligibility: 18 Years and older
Enrollment: 865 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Corona, California • Vista, California

Search by objective public record fields.

Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Urinary KIM-1 After Vancomycin or Linezolid Administration

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)